Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Janssens L, De Puydt J, Milazzo M, Symoens S, De Bleecker JL, Herdewyn S. Risk of malignant hyperthermia in patients carrying a variant in the skeletal muscle ryanodine receptor 1 gene. Neuromuscul Disord 2022;32:864-869. [PMID: 36283893 DOI: 10.1016/j.nmd.2022.10.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2022] [Revised: 10/12/2022] [Accepted: 10/13/2022] [Indexed: 12/15/2022]

For:	Janssens L, De Puydt J, Milazzo M, Symoens S, De Bleecker JL, Herdewyn S. Risk of malignant hyperthermia in patients carrying a variant in the skeletal muscle ryanodine receptor 1 gene. Neuromuscul Disord 2022;32:864-869. [PMID: 36283893 DOI: 10.1016/j.nmd.2022.10.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2022] [Revised: 10/12/2022] [Accepted: 10/13/2022] [Indexed: 12/15/2022]

Number

Cited by Other Article(s)

Herdewyn S, De Bleecker J, Janssens L, Symoens S, Milazzo M, De Puydt J. Response to: The use of guidelines to assess the risk of malignant hyperthermia in individuals with a RYR1 variant. Neuromuscul Disord 2024;35:39. [PMID: 38237271 DOI: 10.1016/j.nmd.2023.11.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2024]

Voermans NC, Yang C, Schouten M, Girard T, Stowell K, Riazi S, Kamsteeg EJ, Snoeck M. The use of guidelines to assess the risk of malignant hyperthermia in individuals with an RYR1 variant. Neuromuscul Disord 2024;35:40-41. [PMID: 38007345 DOI: 10.1016/j.nmd.2023.10.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2023] [Accepted: 10/13/2023] [Indexed: 11/27/2023]

Miyoshi H, Otsuki S, Mukaida K, Kido K, Sumii A, Ikeda T, Noda Y, Yasuda T, Narasaki S, Kato T, Kamiya S, Horikawa YT, Tsutsumi YM. Effects of Remimazolam on Intracellular Calcium Dynamics in Myotubes Derived from Patients with Malignant Hyperthermia and Functional Analysis of Type 1 Ryanodine Receptor Gene Variants. Genes (Basel) 2023;14:2009. [PMID: 38002952 PMCID: PMC10671487 DOI: 10.3390/genes14112009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2023] [Revised: 10/20/2023] [Accepted: 10/24/2023] [Indexed: 11/26/2023] Open

Abstract

Remimazolam is a novel general anesthetic and its safety in patients with malignant hyperthermia (MH) is unknown. We used myotubes derived from the skeletal muscle of patients with MH to examine the response to ryanodine receptor 1 (RYR1) agonist and remimazolam in MH-susceptible patients. Patients underwent muscle biopsy for the Ca2+-induced Ca2+ release (CICR) rate test, a diagnostic tool for MH in Japan. Ten patients had myotubes obtained from skeletal muscle cultures, and the genes associated with malignant hyperthermia in these patients were analyzed. The EC50 of caffeine, cresol, and remimazolam to induce intracellular calcium concentration change were compared between myotubes from CICR-negative genetic test patients and myotubes from other patients. Eight of the ten were CICR-positive, five of whom had RYR1 causative gene mutations or variants. Two patients had CICR-negative genetic tests, and as expected had the highest EC50 (the concentration of a drug that gives a half-maximal response) in response to caffeine, 4CmC and remimazolam. Three patients had a positive CICR but no known variants in RYR1 or CACNA1S (voltage-gated calcium channel subunit alpha1S). Myotubes in these patients had significantly lower EC50s for all agents than myotubes in CICR-negative patients. When myotubes from a patient who was CICR-negative and had no gene variant were used as a control, myotubes from CICR-positive patients were more hyper-responsive than controls to all stimulants used. The EC50 for remimazolam was lowest for myotubes from CICR-positive, RYR1-mutant patients, at 206 µM (corresponding to 123 µg/mL). The concentration was more than 80-times higher than the clinical concentration. RYR1 gene variants in R4645Q and W5020G were shown to be causative gene mutations for MH. Intracellular calcium in myotubes from MH patients are elevated at high concentrations of remimazolam but not at clinically used concentrations of remimazolam. Remimazolam appears to be safe to use in patients with MH.

Collapse

Affiliation(s)

Hirotsugu Miyoshi Department of Anesthesiology and Critical Care, Hiroshima University, Hiroshima 734-8551, Japan; (S.O.); (K.M.); (K.K.); (A.S.); (T.I.); (Y.N.); (S.N.); (T.K.); (S.K.); (Y.M.T.)
Sachiko Otsuki Department of Anesthesiology and Critical Care, Hiroshima University, Hiroshima 734-8551, Japan; (S.O.); (K.M.); (K.K.); (A.S.); (T.I.); (Y.N.); (S.N.); (T.K.); (S.K.); (Y.M.T.)
Keiko Mukaida Department of Anesthesiology and Critical Care, Hiroshima University, Hiroshima 734-8551, Japan; (S.O.); (K.M.); (K.K.); (A.S.); (T.I.); (Y.N.); (S.N.); (T.K.); (S.K.); (Y.M.T.)
Kenshiro Kido Department of Anesthesiology and Critical Care, Hiroshima University, Hiroshima 734-8551, Japan; (S.O.); (K.M.); (K.K.); (A.S.); (T.I.); (Y.N.); (S.N.); (T.K.); (S.K.); (Y.M.T.)
Ayako Sumii Department of Anesthesiology and Critical Care, Hiroshima University, Hiroshima 734-8551, Japan; (S.O.); (K.M.); (K.K.); (A.S.); (T.I.); (Y.N.); (S.N.); (T.K.); (S.K.); (Y.M.T.)
Tsuyoshi Ikeda Department of Anesthesiology and Critical Care, Hiroshima University, Hiroshima 734-8551, Japan; (S.O.); (K.M.); (K.K.); (A.S.); (T.I.); (Y.N.); (S.N.); (T.K.); (S.K.); (Y.M.T.)
Yuko Noda Department of Anesthesiology and Critical Care, Hiroshima University, Hiroshima 734-8551, Japan; (S.O.); (K.M.); (K.K.); (A.S.); (T.I.); (Y.N.); (S.N.); (T.K.); (S.K.); (Y.M.T.)
Toshimichi Yasuda Department of Anesthesiology, Hiroshima Prefectural Rehabilitation Center, Hiroshima 739-0036, Japan;
Soshi Narasaki Department of Anesthesiology and Critical Care, Hiroshima University, Hiroshima 734-8551, Japan; (S.O.); (K.M.); (K.K.); (A.S.); (T.I.); (Y.N.); (S.N.); (T.K.); (S.K.); (Y.M.T.)
Takahiro Kato Department of Anesthesiology and Critical Care, Hiroshima University, Hiroshima 734-8551, Japan; (S.O.); (K.M.); (K.K.); (A.S.); (T.I.); (Y.N.); (S.N.); (T.K.); (S.K.); (Y.M.T.)
Satoshi Kamiya Department of Anesthesiology and Critical Care, Hiroshima University, Hiroshima 734-8551, Japan; (S.O.); (K.M.); (K.K.); (A.S.); (T.I.); (Y.N.); (S.N.); (T.K.); (S.K.); (Y.M.T.)
Yousuke T. Horikawa CHOC Health Alliance, Children’s Hospital Orange County, Orange, CA 92868, USA;
Yasuo M. Tsutsumi Department of Anesthesiology and Critical Care, Hiroshima University, Hiroshima 734-8551, Japan; (S.O.); (K.M.); (K.K.); (A.S.); (T.I.); (Y.N.); (S.N.); (T.K.); (S.K.); (Y.M.T.)

Collapse